A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

作者：Sarit E. Assouline, Laura Christian Michaelis, Megan K. D. Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Ehsan Cheema, Kendra Lynn Sweet, Adam Steven Asch, Jijun Liu, Anna B. Moseley, Tracy Maher, Laura Kingsbury, Min Fang, Jerald P. Radich, Richard F. Little, Harry Paul Erba · 发表于：Leukemia & lymphoma/Leukemia and lymphoma · 年份：2022 · DOI：10.1080/10428194.2022.2148212 · 被引用次数：14 · 研究领域：Acute Myeloid Leukemia Research、Sarcoma Diagnosis and Treatment、Myeloproliferative Neoplasms: Diagnosis and Treatment

Acute myeloid leukemia (AML) primarily affects older adults, for whom lower intensity therapies, such as the hypomethylating agents (HMAs) azacitidine and decitabine, or best supportive care have o...